Advertisement

Cutaneous Lymphomas

  • Lisa Singer
  • Adam Garsa
Chapter

Abstract

Primary cutaneous lymphomas (PCL) encompass primary cutaneous B-cell lymphomas (PCBCL) and primary cutaneous T-cell lymphomas (PCTCL). PCL is a heterogeneous group of disorders classified by the WHO-EORTC, and the treatment varies by subtype. General principles regarding work-up and management paradigms are discussed for a subset of these diseases.

Keywords

Primary cutaneous B-cell lymphoma Primary cutaneous T-cell lymphoma Mycosis fungoides Sézary syndrome 

Notes

Acknowledgment

We thank Amy Gillis, Thomas T. Bui, and Mack Roach III for their work on the prior edition of this chapter.

References

  1. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653–61.PubMedGoogle Scholar
  2. Benner MF, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol. 2009;145(12):1399–404.CrossRefPubMedGoogle Scholar
  3. Compton CC, Byrd DR, Garcia-Aguilar J, et al. In: Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK, editors. AJCC cancer staging atlas. New York: Springer Science & Business Media; 2012.CrossRefGoogle Scholar
  4. Grange F, Joly P, Barbe C, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol. 2014;150(5):535–41.CrossRefPubMedGoogle Scholar
  5. Hoppe RT. Mycosis fungoides: radiation therapy. Dermatol Ther. 2003;16(4):347–54.CrossRefPubMedGoogle Scholar
  6. Hoppe RT, Harrison C, Tavallaee M, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72(2):286–92.CrossRefPubMedGoogle Scholar
  7. Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol. 2002;47(3):364–70.CrossRefPubMedGoogle Scholar
  8. Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome. Arch Dermatol. 2003;139:857–66.PubMedGoogle Scholar
  9. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479–84.CrossRefPubMedGoogle Scholar
  10. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–22.CrossRefPubMedGoogle Scholar
  11. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53:1053–63.CrossRefPubMedGoogle Scholar
  12. Sarris AH, Braunschweig I, Medeiros LJ, et al. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol. 2001;19(2):398–405.CrossRefPubMedGoogle Scholar
  13. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-cell Lymphoma Project. Blood. 2008;111(12):5496–504.CrossRefPubMedGoogle Scholar
  14. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007a;25(12):1581–7.CrossRefPubMedGoogle Scholar
  15. Senff NJ, Hoefnagel JJ, Neelis KJ, et al. Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol. 2007b;143(12):1520–6.CrossRefPubMedGoogle Scholar
  16. Servitje O, Muniesa C, Benavente Y, et al. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients. J Am Acad Dermatol. 2013;69(3):357–64.CrossRefPubMedGoogle Scholar
  17. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol. 2005;153(5):874–80.CrossRefPubMedGoogle Scholar
  18. Smith GL, Wilson LD, Dabaja BS. Mycosis Fungoides. In:Clinical radiation oncology. 4th ed. Philadelphia: Elsevier; 2016. p. 1556–76.CrossRefGoogle Scholar
  19. Specht L, Dabaja B, Illidge T, et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):32–9.CrossRefPubMedGoogle Scholar
  20. Tkachuk DC, Hirschmann JV, Wintrobe MM. Wintrobe’s Atlas of Clinical Hematology. New South Wales: Lippincott Williams & Wilkins; 2007.Google Scholar
  21. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma. Report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46:95–106.CrossRefPubMedGoogle Scholar
  22. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Radiation OncologyUniversity of Texas, MD Anderson Cancer CenterHoustonUSA
  2. 2.Radiation OncologyUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations